Seijong Kim1, Jung Wook Huh2, Woo Yong Lee1, Seong Hyeon Yun1, Hee Cheol Kim1, Yong Beom Cho1, Yoon Ah Park1, Jung Kyong Shin1. 1. Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea. 2. Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea. jungwook.huh@gmail.com.
Abstract
BACKGROUND: The diagnostic impact of lymphovascular invasion (LVI), perineural invasion (PNI), and tumor budding in stage I colon cancer is currently unknown. This study was conducted to evaluate the prognostic impact of LVI, PNI, and tumor budding in stage I colon cancer. METHODS: From January 2008 to December 2013, 720 patients who underwent curative surgery and were diagnosed with stage I colon cancer were reviewed retrospectively. These patients were categorized into two groups based on LVI, PNI, and tumor budding: the no risk group (n = 566) and risk group (n = 154). RESULTS: Median follow-up period was 103.5 months, and the 5-year disease-free survival rate of the risk group was significantly lower than that of the no risk group (p = 0.025). In multivariate analysis, only the risk group had prognostic factors for 5-year disease-free survival (p = 0.036). In addition, only differentiation was an independent predictor in the risk group (p = 0.009). CONCLUSION: LVI, PNI, and tumor budding are strong prognostic factors for stage I colon cancer. Therefore, patients with positive LVI, PNI, or tumor budding should receive close follow-up and potentially be considered for chemotherapy.
BACKGROUND: The diagnostic impact of lymphovascular invasion (LVI), perineural invasion (PNI), and tumor budding in stage I colon cancer is currently unknown. This study was conducted to evaluate the prognostic impact of LVI, PNI, and tumor budding in stage I colon cancer. METHODS: From January 2008 to December 2013, 720 patients who underwent curative surgery and were diagnosed with stage I colon cancer were reviewed retrospectively. These patients were categorized into two groups based on LVI, PNI, and tumor budding: the no risk group (n = 566) and risk group (n = 154). RESULTS: Median follow-up period was 103.5 months, and the 5-year disease-free survival rate of the risk group was significantly lower than that of the no risk group (p = 0.025). In multivariate analysis, only the risk group had prognostic factors for 5-year disease-free survival (p = 0.036). In addition, only differentiation was an independent predictor in the risk group (p = 0.009). CONCLUSION: LVI, PNI, and tumor budding are strong prognostic factors for stage I colon cancer. Therefore, patients with positive LVI, PNI, or tumor budding should receive close follow-up and potentially be considered for chemotherapy.
Authors: Johannes Betge; Peter Kornprat; Marion J Pollheimer; Richard A Lindtner; Andrea Schlemmer; Peter Rehak; Michael Vieth; Cord Langner Journal: Ann Surg Oncol Date: 2012-06-06 Impact factor: 5.344
Authors: Angiolo Gadducci; Sabina Pistolesi; Stefania Cosio; Chiara Comunale; Antonio Fanucchi; Antonio Giuseppe Naccarato Journal: In Vivo Date: 2021 Mar-Apr Impact factor: 2.155
Authors: Giorgio Bianchi; Alfredo Annicchiarico; Andrea Morini; Lorenzo Pagliai; Pellegrino Crafa; Francesco Leonardi; Paolo Dell'Abate; Renato Costi Journal: Int J Colorectal Dis Date: 2021-08-21 Impact factor: 2.571
Authors: Jae Hyun Kang; Il Tae Son; Byung Chun Kim; Jun Ho Park; Jeong Yeon Kim; Jong Wan Kim Journal: Cancer Manag Res Date: 2022-06-20 Impact factor: 3.602